-
Tytuł:
-
Predictive value of microRNA-143 in evaluating the prognosis of patients with hepatocellular carcinoma.
-
Autorzy:
-
Zhang J; Department of Infectious Diseases, The Central Hospital of Linyi City, Linyi 276400, Shandong, China.
Lin H; Department of Gastroenterology, The Central Hospital of Linyi City, Liny 276400, Shandong, China.
Wang XY; Department of Infectious Diseases, The Central Hospital of Linyi City, Linyi 276400, Shandong, China.
Zhang DQ; Department of Infectious Diseases, The Central Hospital of Linyi City, Linyi 276400, Shandong, China.
Chen JX; Department of Reproduction, The Central Hospital of Linyi City, Liny 276400, Shandong, China.
Zhuang Y; Department of Nephrology, The Central Hospital of Linyi City, Liny 276400, Shandong, China.
Zheng XL; Department of Infectious Diseases, The Central Hospital of Linyi City, Linyi 276400, Shandong, China.; Department of Infectious Diseases, Qujing Medical College, Qujing 655000, Yunnan, China.
-
Źródło:
-
Cancer biomarkers : section A of Disease markers [Cancer Biomark] 2017 Jul 04; Vol. 19 (3), pp. 257-262.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Amsterdam ; Washington, DC : IOS Press, c2005-
-
MeSH Terms:
-
Carcinoma, Hepatocellular/*genetics
Liver Neoplasms/*genetics
MicroRNAs/*metabolism
Carcinoma, Hepatocellular/metabolism ; Carcinoma, Hepatocellular/pathology ; Female ; Humans ; Liver Neoplasms/metabolism ; Liver Neoplasms/pathology ; Male ; MicroRNAs/genetics ; Middle Aged ; Predictive Value of Tests ; Prognosis
-
Contributed Indexing:
-
Keywords: MicroRNA-143; hepatocellular carcinoma; predictive value; prognosis
-
Substance Nomenclature:
-
0 (MIRN143 microRNA, human)
0 (MicroRNAs)
-
Entry Date(s):
-
Date Created: 20170425 Date Completed: 20180426 Latest Revision: 20220321
-
Update Code:
-
20240105
-
DOI:
-
10.3233/CBM-160357
-
PMID:
-
28436387
-
Objective: The study aims to evaluate the predictive value of microRNA-143 (miR-143) for the prognosis of patients with hepatocellular carcinoma (HCC).
Methods: Between October 2010 and October 2012, 131 HCC patients were selected as a case group; meanwhile, 122 healthy controls were enrolled as a control group. The miR-143 expression in serum was detected by quantitative real-time polymerase chain reaction (qRT-PCR). These HCC patients were divided into the high miR-143 expression group and the low miR-143 expression group based on the threshold of receiver operating characteristic (ROC) curve. Kaplan-Meier method was applied to analyze the prognosis of HCC patients.
Results: MiR-143 exhibited decreased expression in the case group significantly compared to the control group. The areas under the ROC curve (AUC), sensitivity value and specificity value of the miR-143 expression for the diagnosis of HCC were 0.831, 80.30% and 82.40%, respectively. The miR-143 expression was negatively correlated with vascular invasion, TNM staging, tumor recurrence, metastasis and survival of HCC patients.
Conclusions: Our study provides evidence that miR-143 may be negatively correlated with the prognosis of HCC and provides a promising strategy for HCC treatment and prognosis improvement.
